AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02712723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for ribociclib
Trial: NCT04173104
Drug: [18F]PARPi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
Trial: NCT02998697
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose 200 mg t.i.d for 90 days
Trial: NCT01808547
Drug: ISV-303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075% bromfenac in DuraSite dosed BID
Trial: NCT04459039
Drug: 250 mL 0.9% sterile saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously.
Trial: NCT01068145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules to match SCH 527123, once daily for 7 days
Trial: NCT01068145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules to match SCH 527123, once daily for 14 days
Trial: NCT06785493
Drug: Optimized Treatment (OPT)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the first sufficient intravenous infusion of UST (6 mg/kg), the patient's response was assessed based on PRO2 at week 8, and an individualized treatment plan was developed. At week 8, the patients with incomplete response of PRO2 (a decline of PRO2 was less than 50% from baseline or still in moderate to severe active phase of PRO2) were given one or more UST intravenous re-induction (6 mg/kg) every 4 or 6 weeks.
Trial: NCT00038077
Drug: Seloken ZOK/Toprol-XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg
Trial: NCT00038077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01507311
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose injected subcutaneously (under the skin)
Trial: NCT00451204
Drug: Estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol 8 mg capsule, once per day, duration of treatment is 2 years
Trial: NCT00451204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, once a day, treatment duration is 2 years
Trial: NCT00699426
Drug: placebo+placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo and placebo are tested.
Trial: NCT00711880
Drug: Sativex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Trial: NCT00711880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Trial: NCT04505566
Drug: Ketorolac 0.45% ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
Trial: NCT04505566
Drug: Placebo - Preservative-free artificial tears
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
Trial: NCT02779166
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Received 400mg celecoxib prior to surgery
Trial: NCT02779166
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00317694
Drug: Fermagate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablet 500mg
Trial: NCT00317694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, film coated tablet, 0mg
Trial: NCT03180281
Drug: SU
RxNorm normalized name: SUMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1-2mg qd
Trial: NCT03973268
Drug: Arm 1, 2, 3 drug Interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine
Trial: NCT03973268
Drug: Arm 1 and 2 Interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel
Trial: NCT04267887
Drug: Antiandrogen Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given ADT per standard of care
Trial: NCT06789497
Drug: Lovastatin 60 MG
RxNorm normalized name: lovastatin 60 MG
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were given lovastatin 60 mg/day for three consecutive days.
Trial: NCT06789497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were given placebo 60 mg/day for three consecutive days.
Trial: NCT03907124
Drug: Genetically-guided treatment with FDA-approved psychotropic drugs
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
Trial: NCT03907124
Drug: Treatment as usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
Trial: NCT02115594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04678492
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
Trial: NCT00130533
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00515502
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
Trial: NCT00639873
Drug: quinine-doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quinine-doxycycline for 7 days
Trial: NCT01059565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
Trial: NCT03317002
Drug: AZD5718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of AZD5718 (tablet)
Trial: NCT03317002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (tablet)
Trial: NCT00574587
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
Trial: NCT00574587
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
Trial: NCT01692782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT02139033
Drug: Retaine™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03263429
Drug: Glutaminase Inhibitor CB-839
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT04341116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receive a single infusion
Trial: NCT02212574
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
Trial: NCT01909453
Drug: LGX818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGX818- Orally 100 mg and 50 mg capsules
Trial: NCT01909453
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK162- Orally 15 mg tablets
Trial: NCT06794346
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: women will receive 300mcg of transdermal testosterone in cream daily for six months
Trial: NCT06794346
Drug: Vaginal testosterone gel
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: women will receive 300mcg of vaginal gel testosterone daily for six months
Trial: NCT02298348
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
Trial: NCT04081909
Drug: Fentanyl，Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in OBA ,anesthesia induction will receive fentanyl 2ug/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , remifentanil of 0.1- 0.2ug/ kg/ min.
Trial: NCT01001364
Drug: Foraseq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
Trial: NCT02625480
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT04021862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously.
Trial: NCT00520780
Drug: Ferinject ® (Ferric carboxymaltose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).
Trial: NCT01015391
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
Trial: NCT01654549
Drug: H.pylori eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
Trial: NCT03386279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one single dose by mouth
Trial: NCT04524871
Drug: TPST-1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
Trial: NCT04524871
Drug: NKT2152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKT2152 will be administered by mouth.
Trial: NCT04524871
Drug: IO-108 1200 mg
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.
Trial: NCT03031483
Drug: clarithromycin and lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each treatment course will consist of:~Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg; in case of drug-related adverse events the dose can be reduced to 15 and 10 mg/day; Oral Clarithromycin 500 mg twice daily for 28 days. Courses will be repeated every 28 days. After the first 3 courses patients with stable disease or better response will be given another three courses. Patients with complete remission or disease progression after 6 courses will be taken off study, while patients with partial response or stable disease will receive 3 further courses of treatment. Again, patients with complete response or disease progression will stop therapy, while patients with partial response/stable disease will receive 3 further courses up to a maximum of 12 courses in total.
Trial: NCT00353496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
Trial: NCT03997123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
Trial: NCT03127514
Drug: AMX0035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMX0035
Trial: NCT04105010
Drug: AZD4205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
Trial: NCT02738138
Drug: ABT-493 coformulated with ABT-530
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01638910
Drug: EV/DNG (Qlaira, BAY86-5027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
Trial: NCT04335045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1\~8 Placebo capsule(s) corresponding to each PH100 dose
Trial: NCT04335045
Drug: PH100 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 100 mg PH100 oral capsule
Trial: NCT04335045
Drug: PH100 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 200 mg PH100 oral capsule
Trial: NCT04335045
Drug: PH100 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 200 mg PH100 oral capsules
Trial: NCT04335045
Drug: PH100 800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 200 mg PH100 oral capsules
Trial: NCT04335045
Drug: PH100 1200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 x 200 mg PH100 oral capsules
Trial: NCT04335045
Drug: PH100 1600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 x 200 mg PH100 oral capsules
Trial: NCT06798051
Drug: Roxithromycin tablets 150mg
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral roxithromycin tablets，150mg Once every seven days，One cycle T drug, two cycles R drug
Trial: NCT03907826
Drug: GP
RxNorm normalized name: GPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
Trial: NCT02890355
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02890355
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV bolus
Trial: NCT02890355
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03524092
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04224246
Drug: Gamma Hydroxybutyrate
RxNorm normalized name: Gamma hydroxybutyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
Trial: NCT04299191
Drug: LAM561
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general criterion) is met.~The starting dose will be 2.8 g/m2 twice daily. If tolerated, doses will be escalated to 3.5 g/m2 twice daily and then to a third dose level of 4.2 g/m2 twice daily. These dose levels correspond to 80%, 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. A total of 3 dose cohorts are anticipated for the dose escalation phase of the study, with up to 6 patients enrolled at each dose level according to a standard 3+3 design. During each dose cohort, at least 1 week must elapse between the first and subsequent patients receiving treatment with LAM561.
Trial: NCT03971669
Drug: Vivotif Typhoid Oral Vaccine
RxNorm normalized name: Vivotif Typhoid Oral Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Trial: NCT00001452
Drug: oCRH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02533973
Drug: Xamiol® gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02533973
Drug: Daivonex® scalp solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02415127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
Trial: NCT06745986
Drug: Spinal Anesthesia (bupivacaine)
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spinal anesthesia by 2.5 ml bupivacaine 0.5%
Trial: NCT03133195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)
Trial: NCT01855750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 matched capsules administered by mouth once daily (21-day cycles)
Trial: NCT01855750
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Trial: NCT01855750
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Trial: NCT02905942
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
Trial: NCT04303117
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg administered IV every two weeks while on NHS-IL12.
Trial: NCT00650078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x daily
Trial: NCT03703271
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single-agent 5-day methotrexate, two weeks a cycle
Trial: NCT04043494
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Trial: NCT04043494
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of standard chemotherapy
Trial: NCT04043494
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Trial: NCT04043494
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
Trial: NCT02513394
Drug: Standard Adjuvant Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02017613
Drug: RP6530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses starting at 25 mg BID
Trial: NCT00344955
Drug: HMG-CoA reductase inhibition (atorvastatin)
RxNorm normalized name: HMG CoA reductase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00448760
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles